Exclusive: Japan’s Astellas looks to sell dermatology assets – sources

By Jessica Toonkel NEW YORK (Reuters) – Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation. Astellas has hired London-based investment banking boutique DC Advisory to sell the assets, according to two of the people, who wished to remain anonymous because they are not permitted to speak to the press. The company's dermatology portfolio, which includes a drug to treat eczema called Protopic, sells products around the world. …